JP2019519584A - アミロイドーシスを処置するための組成物 - Google Patents

アミロイドーシスを処置するための組成物 Download PDF

Info

Publication number
JP2019519584A
JP2019519584A JP2018568771A JP2018568771A JP2019519584A JP 2019519584 A JP2019519584 A JP 2019519584A JP 2018568771 A JP2018568771 A JP 2018568771A JP 2018568771 A JP2018568771 A JP 2018568771A JP 2019519584 A JP2019519584 A JP 2019519584A
Authority
JP
Japan
Prior art keywords
antibody
patient
use according
seq
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018568771A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519584A5 (enExample
Inventor
ジーン ジー． キニー，
ジーン ジー． キニー，
スペンサー ディー． ガスリー，
スペンサー ディー． ガスリー，
マーティン コラー，
マーティン コラー，
Original Assignee
プロシーナ バイオサイエンシーズ リミテッド
プロシーナ バイオサイエンシーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロシーナ バイオサイエンシーズ リミテッド, プロシーナ バイオサイエンシーズ リミテッド filed Critical プロシーナ バイオサイエンシーズ リミテッド
Publication of JP2019519584A publication Critical patent/JP2019519584A/ja
Publication of JP2019519584A5 publication Critical patent/JP2019519584A5/ja
Priority to JP2022106974A priority Critical patent/JP2022121658A/ja
Priority to JP2024108049A priority patent/JP2024127990A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018568771A 2016-06-30 2017-06-30 アミロイドーシスを処置するための組成物 Withdrawn JP2019519584A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022106974A JP2022121658A (ja) 2016-06-30 2022-07-01 アミロイドーシスを処置するための組成物
JP2024108049A JP2024127990A (ja) 2016-06-30 2024-07-04 アミロイドーシスを処置するための組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357151P 2016-06-30 2016-06-30
US62/357,151 2016-06-30
PCT/US2017/040289 WO2018005967A1 (en) 2016-06-30 2017-06-30 Compositions for treating amyloidosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022106974A Division JP2022121658A (ja) 2016-06-30 2022-07-01 アミロイドーシスを処置するための組成物

Publications (2)

Publication Number Publication Date
JP2019519584A true JP2019519584A (ja) 2019-07-11
JP2019519584A5 JP2019519584A5 (enExample) 2020-08-13

Family

ID=59351103

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018568771A Withdrawn JP2019519584A (ja) 2016-06-30 2017-06-30 アミロイドーシスを処置するための組成物
JP2022106974A Withdrawn JP2022121658A (ja) 2016-06-30 2022-07-01 アミロイドーシスを処置するための組成物
JP2024108049A Pending JP2024127990A (ja) 2016-06-30 2024-07-04 アミロイドーシスを処置するための組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022106974A Withdrawn JP2022121658A (ja) 2016-06-30 2022-07-01 アミロイドーシスを処置するための組成物
JP2024108049A Pending JP2024127990A (ja) 2016-06-30 2024-07-04 アミロイドーシスを処置するための組成物

Country Status (16)

Country Link
US (2) US20190169280A1 (enExample)
EP (1) EP3478713B1 (enExample)
JP (3) JP2019519584A (enExample)
CY (1) CY1125536T1 (enExample)
DK (1) DK3478713T3 (enExample)
ES (1) ES2914781T3 (enExample)
HR (1) HRP20220979T8 (enExample)
HU (1) HUE059400T2 (enExample)
LT (1) LT3478713T (enExample)
MA (1) MA45552A (enExample)
PL (1) PL3478713T3 (enExample)
PT (1) PT3478713T (enExample)
RS (1) RS63446B1 (enExample)
SI (1) SI3478713T1 (enExample)
SM (1) SMT202200261T1 (enExample)
WO (1) WO2018005967A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505923A (ja) * 2021-01-29 2024-02-08 プロシーナ バイオサイエンシーズ リミテッド Ａｌアミロイドーシスを処置する方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210017278A1 (en) * 2018-03-23 2021-01-21 Prothena Biosciences Limited Treatment and Prophylaxis of Amyloidosis
CA3129890A1 (en) * 2019-02-12 2020-08-20 Prothena Biosciences Limited Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells
MA55209A (fr) 2019-03-05 2022-01-12 Prothena Biosciences Ltd Procédés de traitement de l'amylose al
EP4022062A1 (en) * 2019-08-30 2022-07-06 Alnylam Pharmaceuticals, Inc. Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy
EP4168451A2 (en) * 2020-06-22 2023-04-26 NGM Biopharmaceuticals, Inc. Lair-1-binding agents and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530917A (ja) * 2011-10-25 2014-11-20 オンクレーヴセラピューティクス リミテッド 抗体製剤および方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2009086539A2 (en) 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530917A (ja) * 2011-10-25 2014-11-20 オンクレーヴセラピューティクス リミテッド 抗体製剤および方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNALS OF NEUROLOGY, vol. 6(1), JPN6021024273, 1979, pages 1 - 7, ISSN: 0004715915 *
MOUNT SINAI JOURNAL OF MEDICINE, vol. 79(6), JPN6021024276, 2012, pages 733 - 748, ISSN: 0004715917 *
MUSCLE AND NERVE, vol. 36, JPN6021024274, 2007, pages 411 - 423, ISSN: 0004715916 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024505923A (ja) * 2021-01-29 2024-02-08 プロシーナ バイオサイエンシーズ リミテッド Ａｌアミロイドーシスを処置する方法

Also Published As

Publication number Publication date
SI3478713T1 (sl) 2022-06-30
EP3478713B1 (en) 2022-05-11
PT3478713T (pt) 2022-05-27
HRP20220979T1 (hr) 2022-11-11
MA45552A (fr) 2019-05-08
US20210079078A1 (en) 2021-03-18
JP2024127990A (ja) 2024-09-20
RS63446B1 (sr) 2022-08-31
CY1125536T1 (el) 2025-05-09
HUE059400T2 (hu) 2022-11-28
DK3478713T3 (da) 2022-06-20
US20190169280A1 (en) 2019-06-06
EP3478713A1 (en) 2019-05-08
WO2018005967A1 (en) 2018-01-04
PL3478713T3 (pl) 2022-10-10
JP2022121658A (ja) 2022-08-19
LT3478713T (lt) 2022-06-10
ES2914781T3 (es) 2022-06-16
HRP20220979T8 (hr) 2023-02-03
SMT202200261T1 (it) 2022-07-21

Similar Documents

Publication Publication Date Title
JP2024127990A (ja) アミロイドーシスを処置するための組成物
US20250186460A1 (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
JP2018138551A (ja) 関節リウマチの治療
KR20220019656A (ko) 경쇄 아밀로이드증 치료 방법
US20250075007A1 (en) Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
Ashfaque et al. Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
TW202346335A (zh) 治療al類澱粉變性症之方法
KR20230136643A (ko) Al 아밀로이드증 치료 방법
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
HK40008815B (en) Compositions for treating amyloidosis
US20250312339A1 (en) Methods and compositions comprising a shp2 inhibitor and a pd-li binding antagonist
US20250376530A1 (en) Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody
RU2802812C2 (ru) Лечебный подход, предназначенный для лечения комбинацией антитела к CD19 и венетоклакса
WO2023160517A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
CA3095100A1 (en) Treatment and prophylaxis of amyloidosis
EA044759B1 (ru) Лечение и профилактика амилоидоза
HK40025659B (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210922

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220701

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220701

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220711

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220712

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220714